MedDataX Logo

Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study

NCT ID: NCT03186976

Last Updated: 2019-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-01

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot study to assess feasibility to conduct a multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on the atrial substrate, which is involved in the development and maintenance of atrial fibrillation (AF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It is associated with a six-fold risk of stroke and a two-fold increase in mortality, the main cardiac reason for death one year after presenting to the emergency department with AF is heart failure. It results in high healthcare costs, recurrent ED visits and hospitalizations. The burden of disability associated with AF has been found to increase by 20% from 1990-2010. AF was also cited as one of the seven causes of death that has been increasing worldwide. Prevention of AF has not been a focus of past treatments and it is well known that elevated body mass index, hypertension, smoking, increased alcohol intake, lack of exercise and sleep apnea are risk factors for AF. There is a lack of randomized, multicenter data proving that a strategy of aggressive risk factor modification will prevent and modify AF.

Upstream therapy for AF has been of considerable interest, and benefit has been demonstrated in primary prevention of AF. Catheter ablation has demonstrated success over current medical therapies for long-term rhythm control, but recurrence remains high, irrespective of ablation strategy. This study is a feasibility study to determine whether a complex and multi-component risk factor modification can be successfully implemented.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Risk Factor Modification Catheter ablation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This will be a parallel group, open label randomized clinical trial, with blinded endpoint evaluation (PROBE design)
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aggressive Risk Factor Control

Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management

Group Type EXPERIMENTAL

Aggressive Risk Factor Control

Intervention Type BEHAVIORAL

1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.

2\) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).

3\) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.

4\) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.

5\) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%

Standard of Care

All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.

Group Type ACTIVE_COMPARATOR

Standard of Care

Intervention Type OTHER

Recommendations based on current guidelines

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aggressive Risk Factor Control

1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.

2\) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).

3\) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.

4\) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.

5\) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%

Intervention Type BEHAVIORAL

Standard of Care

Recommendations based on current guidelines

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with symptomatic (CCS-SAF ≥2) recurrent paroxysmal or persistent nonvalvular atrial fibrillation despite rate control, desiring catheter ablation AND
* one of : BMI\>27, BP\>140/90 or history of hypertension, alcohol use \> recommended limit, current smoking, diabetes with HgA1C\>7%, physical inactivity (\<150 minutes/week).

(Definitions: Recurrent paroxysmal - at least 4 episodes of symptomatic AF in the prior 6 months, with or without cardioversion; Persistent AF lasting greater than 7 days but less than 3 years; AF must be documented on a Holter, rhythm strip or electrocardiogram within the last 24 months.)

Exclusion Criteria

* Permanent AF (AF lasting \> 3 years)
* Prior catheter ablation for AF
* Left ventricular ejection fraction \<30%
* Left atrial size \> 5.5 cm
* NYHA IV heart failure
* Participation in a cardiac rehabilitation program within the last year
* Currently performing exercise training 150 minutes/week of moderate to vigorous physical activity
* Unable to exercise
* Unable to give informed consent
* Other noncardiovascular medical condition making 1 year survival unlikely
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Canadian Cardiovascular Society

OTHER

Sponsor Role collaborator

Nova Scotia Health Authority

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ratika Parkash

MD, FRCPC

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ratika Parkash

Role: PRINCIPAL_INVESTIGATOR

Nova Scotia Health Authority

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

QE II Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RP-004

Identifier Type: -

Identifier Source: org_study_id